Stories

The IRE Resource Center is a major research library containing more than 27,000 investigative stories.

Most of our stories are not available for download but can be easily ordered by contacting the Resource Center directly at 573-882-3364 or rescntr@ire.org where a researcher can help you pinpoint what you need.

Search results for "Stricharchuk" ...

  • Unfaithful

    Priest who leave the Catholic Church, regardless of how many years or decades they have served, are cut off from receiving any retirement pension or benefits. Meanwhile, Church officials acknowledge that they financially support priests convicted of crimes (including child molestation). Churches are exempt from filing their pension plans with any governmental agency. The only option for a priest to recover a pension is to take the Church to court, a prohibitively costly action. This financial dependence prevents priests from leaving the church to pursue other careers or to marry. Many have secret lovers, wives and even children hidden for years. In some cases, they father children but must be forced by the states to pay child support.
  • (Untitled)

    Wall Street Journal chronicles how a foreman at General Electric's jet engine plant was fired for refusing to cheat on a government contract; documents systematic corruption at the plant, June 23, 1988.
  • (Untitled)

    Wall Street Journal reveals Dow Chemical Co. has tried to maintain a low profile on the problems surrounding Sarabond, a product that strengthens mortar; reveals the product, first used in 1965, apparently corrodes steel, prompting several lawsuits against Dow as buildings and tunnels begin to crumble, March 21, 1989.
  • (Untitled)

    Wall Street Journal discusses how Ernst & Whinney's unqualified audit of United American Bank in Knoxville, Tenn., missed the boat, with UAB collapsing just weeks after the report was issued, March 1983.
  • Pharmaceutical Testing Fraud

    Wall Street Journal details how a Vitarine Pharmaceuticals employee cracked open capsules of another company's blood-pressure drug, had the contents tested, and sent along the results to the FDA as if it were Vitarine's own new drug; finds Vitarine made millions of dollars after the FDA gave approval, although the FDA eventually discovered the con; finds the FDA has trouble uncovering all the drug switches attempted by generic drug companies.